Dendritic cell vaccination in medullary thyroid carcinoma
/in Dendritic Cells, International Publications, Thyroid CancerTumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
/in Dendritic Cells, International Publications, Multiple MyelomaTransient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
/in Brain Tumors in Children, Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenCharacterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis
/in Dendritic Cells, International Publications, Soft Tissue SarcomaGeneration of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides
/in Colorectal Cancer, Dendritic Cells, International PublicationsCytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaAccomplishments and perspectives of immunological interventions in lymphoproliferative disorders
/in Dendritic Cells, International Publications, Multiple MyelomaTumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity
/in Dendritic Cells, Hyperthermia, International PublicationsVaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
/in Breast Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer